The brave new world of global P&MA under MFN: Simon-Kucher views and expertise

Published on January 7, 2026

The proposed US Most Favored Nation (MFN) policy has the potential to significantly influence global P&MA strategy development, but its impact will likely even go far beyond this, affecting diverse corporate functions such as e.g. R&D, BD&L, and commercial. While many questions remain, pharmaceutical and biotech companies are already evaluating how they can prepare for a range of possible outcomes.

In this webinar, Simon-Kucher experts will share their latest perspectives on the MFN policy, discuss what it could mean for global pricing and market access, and explore practical approaches to preparing commercial strategies and designing global P&MA strategies in an uncertain environment.

Participants will learn:

  • The latest developments and our early perspectives on the potential impact of the US MFN policy on global P&MA and beyond
    • …

    MFN Webinar

Continue reading on website
Other news

Financial Services NY executive dinner

January 7, 2026
Join us for an exclusive evening designed for senior executives in Financial Services and Private Equity. Hosted at Per Se, Chef Thomas Keller's renowned three Michelin-starred restaurant overlooking Central Park, this private dinner offers an exceptional culinary experience alongside meaningful conversations with industry leaders shaping the future of finance. More than a memorable dining experie

Most Favored Nation (MFN) pricing and its impact on pharma asset valuation, M&A, and licensing

February 2, 2026
table {border-collapse: collapse;font-size: 12px;}table td {border: 1px solid black;padding: 5px;}table tr:first-child td img{display: inline-block;}table tr:first-child td p{display: inline-block;vertical-align: middle;}table tr:first-child td:nth-child(2) {background-color: #DAF5F5;color: #2DA1A1;}table tr:first-child td:nth-child(3) {background-color: #CBECFA;color: #0F7199;}table tr:first-chil